Related Experiment Video
Updated: Feb 10, 2026

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling
Published on: August 3, 2018
A targeted transforming growth factor-beta (TGF-β) blocker, TTB, inhibits tumor growth and metastasis
Changhua Zhou1,2, Jing Li1,2, Limin Lin1,2
1School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Abstract:
Transforming growth factor beta (TGF-β) promotes cancer growth in late stage cancers. To inhibit the TGF-β pathway, we investigated a tumor-targeting TGF-β receptor blocker, TTB, and its role in tumor progress. The targeted TTB comprised of the extracellular domain of the TGF-β receptor II, the endoglin domain of TGF-β receptor III, and the human immuno-globin IgG1 constant fragment (Fc). To enhance tumor microenvironment targeting, a RGD peptide was fused at the N-terminal of TTB. The targeted TTB exhibited potent TGF-β neutralization activities, and inhibited cancer cell migration and invasion as well as colony formation. In xenograft models, the TTB had potent tumor inhibition activities. The TTB also attenuated the TGF-β1-induced Smad2 phosphorylation and epithelial to mesenchymal transformation (EMT), and suppressed breast cancer metastasis. Thus, the TTB is an effective TGF-β blocker with a potential for blocking excessive TGF-β induced pathogenesis in vivo.
Insights
A novel tumor-targeting TGF-β receptor blocker (TTB) effectively inhibits cancer progression and metastasis. This targeted therapy shows potent anti-cancer activity in preclinical models, offering a promising approach for late-stage cancers.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Transforming growth factor beta (TGF-β) is a key driver of cancer progression in advanced stages.
- Targeting the TGF-β pathway is a therapeutic strategy to inhibit tumor growth and metastasis.
Purpose of the Study:
- To investigate the efficacy of a novel tumor-targeting TGF-β receptor blocker (TTB) in inhibiting cancer progression.
- To evaluate the therapeutic potential of TTB in preclinical cancer models.
Main Methods:
- TTB was engineered by fusing the TGF-β receptor II extracellular domain, TGF-β receptor III endoglin domain, and human IgG1 Fc fragment.
- An RGD peptide was incorporated for enhanced tumor microenvironment targeting.
- In vitro assays assessed TGF-β neutralization, cell migration, invasion, and colony formation.
- In vivo studies utilized xenograft models to evaluate tumor inhibition and metastasis suppression.
Main Results:
- TTB demonstrated potent TGF-β neutralization activity in vitro.
- TTB significantly inhibited cancer cell migration, invasion, and colony formation.
- In vivo, TTB exhibited significant tumor inhibition and suppressed breast cancer metastasis.
- TTB attenuated TGF-β1-induced Smad2 phosphorylation and epithelial-to-mesenchymal transition (EMT).
Conclusions:
- The engineered TTB is an effective TGF-β pathway inhibitor.
- TTB demonstrates strong anti-tumor and anti-metastatic potential in preclinical settings.
- TTB represents a promising therapeutic candidate for blocking TGF-β-induced pathogenesis in vivo.
Related Concept Videos
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Population Growth
TGF - β Signaling Pathway
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: Osmolarity

